New money to extend the runway
Arecor Therapeutics plc (LSE:AREC), the Cambridge-based clinical-stage biotech, has raised fresh capital to support its insulin development programmes and negotiations with insulin pump companies. On 30 September 2026 it published interim results for the six months to 30 June 2026 and, on the same day, launched a fundraising of up to £5.13m. A placing of 7,352,941 new shares at 68p raised about £5.0m gross, with a retail offer of up to £130,000 alongside it; the result of the retail offer was announced on 7 October. The chief executive said the raise would extend the company's cash runway to December 2027.
What the company does
Arecor develops therapeutics for diabetes, obesity and other cardiometabolic diseases, using formulation technology to improve existing medicines. Its lead programmes are ultra-rapid-acting insulins. AT278 is an ultra-concentrated insulin at 500 units per millilitre, being co-developed with Sequel Med Tech towards Phase 2 readiness. AT290 is a concentrated 200 units per millilitre version, and AT247 is a standard-strength U100 insulin. The company is also undertaking preclinical work on an oral GLP-1 candidate.
Latest developments
Arecor said discussions with several insulin pump companies about bringing an insulin and automated insulin delivery combination to market had reached term sheet stage. Negotiations with Sequel Med Tech over further agreements are ongoing. A planned Phase 2 study for AT290 would be a six-week crossover trial of about 90 subjects, compared against NovoLog, with time-in-range as the primary endpoint. On 13 August 2026 the company announced that AT278 clinical data had been published in a peer-reviewed journal, Diabetes, Obesity and Metabolism.
The company previously sold royalty rights to Ligand Pharmaceuticals for $7m upfront in September 2025, and has received further milestone payments, with up to $3.0m more payable on commercial milestones. Its former Tetris Pharma subsidiary has been discontinued.
Financial picture
Revenue in the first half fell to £194,000 from just over £1.0m, as partner revenue declined and royalty income ceased following the royalty sale. R&D spending rose to £1.87m, driven by insulin manufacturing costs, and the operating loss widened to £3.16m from £2.09m. Cash, cash equivalents and short-term investments were £3.2m at 30 June 2026. For the full year, the board guided to revenue of about £0.3m and a loss after tax of about £5.5m. No dividend is paid.
Sector and index context
Arecor is one of a number of early-stage life sciences companies in the FTSE AIM All Share Index. Diabetes technology is a large and competitive market, with growing use of insulin pumps and automated delivery systems creating demand for insulins that act faster or come in more concentrated forms. Small biotech companies have generally found fundraising difficult, which makes partnering progress important.
Key risks
The company remains loss-making with limited revenue, and future programmes may require more capital. Partnering discussions may not result in signed deals. Clinical trials can fail or be delayed, and regulatory paths for new insulin formulations involve uncertainty. Larger competitors dominate the insulin market.
What to watch next
Investors will look for conversion of pump company term sheets into binding agreements, progress with Sequel Med Tech, the start of Phase 2 work and any further milestone receipts. Full-year results for 2026 will show whether spending stays within guidance, and whether the new funding is sufficient to reach the clinical and commercial milestones management has set out.






Please wait processing your request...